ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Highly-sensitized"

  • 2022 American Transplant Congress

    Regulatory T Cells Suppress Memory IFN-Gamma Production in Highly Sensitised Patients

    C. Dudreuilh1, S. Basu1, O. Shaw2, H. Burton1, C. Domingo-Vila1, T. Tree1, G. Lombardi1, C. Scotta1, A. Dorling1

    1King's College London, London, United Kingdom, 2Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom

    *Purpose: Highly sensitized patients (HS) present worse long-term outcome after transplantation compared to those without donor-specific antibodies (DSA). It has been suggested that desensitisation using…
  • 2022 American Transplant Congress

    Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up

    A. Vo1, J. Tang1, N. Ammerman1, E. Huang1, X. Zhang2, M. Haas3, A. Peng1, R. Najjar1, S. Williamson1, C. Meyers1, S. Sethi1, K. Lim1, M. Gillespie1, N. Badash1, S. Jordan1

    1Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, 2HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, 3Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA

    *Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…
  • 2022 American Transplant Congress

    CIAT: A New Kidney Exchange Program with Better Options for Highly Sensitized and Long Waiting Patients

    M. d. Klerk1, J. Kal1, D. L. Roelen2, M. Betjes1, A. Weerd de1, M. Reinders1, M. Kho1, K. Glorie3, J. I. Roodnat1

    1Internal Medicine, Erasmus MC Transplant Institute, Rotterdam, Netherlands, 2Immunology, Leids UMC, Netherlands, 3Econometrics, EUR, Rotterdam, Netherlands

    *Purpose: A number of alternative, both living and deceased donor kidney transplant programs have been developed for incompatible pairs and difficult to match patients. The…
  • 2022 American Transplant Congress

    Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population

    A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran

    University of Illinois at Chicago, Chicago, IL

    *Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
  • 2021 American Transplant Congress

    Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience

    A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, K. Lim, M. Gillespie, S. C. Jordan

    Cedars Sinai Medical Ctr, Los Angeles, CA

    *Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…
  • 2021 American Transplant Congress

    Rabbit Anti-thymocyte Globulin Induction Dosing Strategies in a High-risk Kidney Transplant Population

    C. Nguyen, R. Yau, C. Tunwar

    Pharmacy, CHI Baylor St. Luke's Medical Center, Houston, TX

    *Purpose: The objective of this retrospective observational study is to compare the safety and efficacy of two dosing strategies, rabbit anti-thymocyte globulin (rATG) at a…
  • 2021 American Transplant Congress

    First Promising Results of CIAT: A New Kidney Exchange Program for Difficult-to-match Patients

    M. de Klerk1, J. Kal1, K. Glorie2, D. Roelen3, M. Betjes1, J. Wetering van de1, M. Kho1, J. Roodnat1

    1Erasmus MC, Rotterdam, Netherlands, 2EQI, Erasmus University, Rotterdam, Netherlands, 3LUMC, Leiden, Netherlands

    *Purpose: Computerised Integration of Alternative Transplantation (CIAT) programs was developed to increase the chances of highly immunized (HI) and longwaiting (LW) kidney transplant candidates. CIAT…
  • 2021 American Transplant Congress

    Kidney Transplantation in Very Highly-Sensitized Patients with Maastricht Type III Non-heart-Beating Donors

    F. Villanego1, A. Mazuecos1, L. Vigara1, V. Lopez2, G. Bernal3, A. Rodriguez-Benot4, M. de Gracia5, P. Castro6, A. Alvarez6

    1Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain, 2Department of Nephrology, Hospital Carlos Haya, Malaga, Spain, 3Department of Nephrology, Hospital Virgen del Rocio, Sevilla, Spain, 4Department of Nephrology, Hospital Reina Sofia, Cordoba, Spain, 5Department of Nephrology, Hospital Virgen de las Nieves, Granada, Spain, 6Andalusian Transplant Coordination, Sevilla, Spain

    *Purpose: In 2012, a kidney transplant (KT) program for very highly-sensitized (VHS) patients (PRA ≥ 95%) based on virtual crossmatch began in Andalusia (Spanish region).…
  • 2021 American Transplant Congress

    Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation

    B. Oh1, F. Messner2, Y. Guo1, G. Brandacher1

    1Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Innsbruck, Austria

    *Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
  • 2021 American Transplant Congress

    Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)

    A. A. Vo1, N. Ammerman1, E. Huang1, M. Toyoda2, S. Ge2, A. Peng1, R. Najjar1, S. Sethi1, S. Williamson1, C. Myers1, K. Lim1, M. Gillespie1, S. Jordan1

    1Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, 2Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA

    *Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences